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A b st r a ct : T H E D E V E L O P M E N T A N D V A L ID A T O N O F A N O V E L IC H T H Y O S IS
S E V E R IT Y A S S E S S M E N T IN S T R U M E N T .
Q isi S u n , A m y P aller, K eith A . C h o ate. D ep artm en t o f D erm ato lo g y, G en etics &
P ath o lo g y, Y ale U n iv ersity S ch o o l o f M ed icin e, N ew H av en , C T .
Ich th yo sis clin ical trials req u ire reliab le, v alid ated sev erity assessm en ts to id en tify
ap p ro p riate su b jects an d q u an tify treatm en t o u tco m es. T h ere is n o v alid ated scale to
m easu re ich th yo sis sev erity acro ss th e en tire b o d y. W e aim to create an d v alid ate a
co m p reh en siv e an d u ser-frien d ly in stru m en t to m easure to tal b o d y ich th yo sis sev erity in
ad u lts an d ch ild ren .
W e d iv id ed th e b o d y in to 1 0 regio n s to sco re sp ecial regio n s o f in terest. L ik ert scales (0 4 ) w ere estab lish ed to q u an tify scale an d eryth em a, w ith d escrip to rs an d p h o to grap h ic
stan d ard s. A n 8 3 -im ag e teach in g set w as created fro m p h o to grap h s o f ich th yo sis p atien ts,
S ix d erm ato lo gists sco red all test p h o to grap h s tw ice to ev alu ate in tra-rater reliab ility.
In tra-class co rrelatio n co efficien ts (IC C s) d eterm in ed th e o v erall reliab ility o f o u r
in stru m en t.
T h e IC C fo r co m b in ed scale an d eryth em a sco res across th e en tire b o d y is 0 .9 0 3 (9 5 %
C I, 0 .7 7 -0 .9 7 4 ). IC C s fo r scale an d eryth em a su b -sco res are 0 .9 1 1 (9 5 % C I, 0 .7 8 9 -0 .9 7 6 )
an d 0 .8 8 2 (9 5 % C I, 0 .7 2 3 -0 .9 6 8 ), resp ectiv ely. B o d y sites ex h ib ited m o d erate-go o d in terrater reliab ilities fo r scale, ex cep t elb o w s an d low er ex trem ities. E ryth em a reliab ilities
acro ss all b o d y sites w ere m o d erate-ex cellen t. In tra-rater reliab ilities w ere ex cellen t (IC C
> 0 .9 ).
T h e IS S is v alid ated as a co m p reh en siv e to o l fo r assessin g ich th yo sis sev erity acro ss th e
en tire b o d y.
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I n t r o d u ct io n
T h e ich th yo ses are a h etero g en o u s gro u p o f g en etic sk in d iso rd ers featu rin g scale an d
eryth em a w ith o r w ith o u t asso ciated s ystem ic fin d ings. M u tatio n s in o v er 5 0 gen es cau se
ich th yo sis, an d th eir co m m o n p ath o gen esis is ab n o rm al b arrier fu n ctio n an d in creased
tran sep id erm al w ater lo ss w ith en su in g co m p en sato ry h yp erp ro liferatio n . M o st are
in h erited , b u t acq u ired ich th yo sis can arise fro m m align an c y, au to im m u n e o r
in flam m ato ry d isease, n u tritio n al d eficien c y an d m ed icatio n s. 1 In h erited ich th yo ses are
classified in to syn d ro m ic an d n o n -s yn d ro m ic fo rm s.

In D r. K eith C h o ate’s lab o rato ry, w e seek to u n d erstan d th e fu n d am en tal m ech an ism s o f
rare g en o d erm ato ses u sin g to o ls o f h u m an gen etics. In ad d itio n , w e m an ag e th e N atio n al
R egistry fo r Ich th yo sis an d R elated D iso rd ers in co llab o ratio n w ith th e F o u n d atio n fo r
Ich th yo sis an d R elated S k in T yp es (F .I.R .S .T ). O v er th e years, w e h av e serv ed as th e
m ajo r n atio n al an d in tern atio n al referral cen ter for rare g en o d erm ato ses an d h av e
recru ited o v er 1 4 0 0 k in d red s w ith d iso rd ers o f k eratin izatio n . W e u tilized w h o le ex o m e
seq u en cin g fo r n o v el gen e d isco v ery an d seq u en ced p aren t-ch ild trio s to id en tify d e n o vo
m u tatio n s an d p aired gen o m ic an d affected tissu e D N A sam p les w h en so m atic m o saicism
is su sp ected . O u r w o rk h as led to sign ifican t d isco v eries th at h av e en h an ced o u r
u n d erstan d in g o f th e p ath o gen esis o f sk in d isease an d tran sfo rm ed p atien t care.

In th e fo llo w in g sectio n s, w e w ill fo cu s o n th e n o n -syn d ro m ic ich th yo ses, first p ro v id in g
a b rief o v erv iew o f th e d ifferen t typ es b efo re id entifyin g an im p o rtan t n eed in th e field
th at serv ed as th e m o tiv atio n b eh in d th is th esis p ro ject.
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P h en o typ ic featu res o f su b jects w ith th is gen o typ e are sh o w n in F ig. 1 . 8 7 % o f th e
su b jects su rv e yed w ith TG M 1 m u tatio n s w ere b o rn w ith a co llo d io n p resen tatio n , a tigh t,
sh in y, p arch m en t-lik e m em b ran e th at en cases th e n eon ate, resu ltin g in ectro p io n an d
eclab io n . T h e ch aracteristic ap p earan ce o f ich th yo sis cau sed b y TG M 1 m u tatio n s is flat,
d ark , p late-lik e scale in lam ellar ich th yo sis an d fin e, w h ite, su p erficial scales w ith m ild to
m o d erate d eg rees o f eryth em a an d ectro p io n in co n gen ital ich th yo sifo rm eryth ro d erm a.

F ig u r e 1 . P h en o t y p es o f ich t h y o sis d u e t o T G M 1 m u t a t io n s. (a -e) T h e ch aracteristic
ap p earan ce o f su b jects w ith TG M 1 m u tatio n s in clu d e flat, p late-lik e scales in a m o saic
p attern an d m ild to m o d erate eryth em a. P h en o typ es ran ge fro m d isco n tin u o u s
sm o o th en in g (d im in ish ed fin e sk in m ark in gs, sh in in ess) (f), co n flu en t scales w ith p in k
eryth em a (g ), an d co n flu en t, p rim arily large (> 1 cm ) p late-lik e th ick scales (h ).
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Figure 2. Phenotypes of ichthyosis due to ABCA12 mutations
(a-e) The characteristic appearance of ichthyosis caused by ABCA12 mutations include
significant and often severe erythema with fine white or thick lamellar scale and
palmoplantar keratoderma. (d-g) Distinguishing features include tapered digits,
hyperconvex nails, and pyknotic ears. Clinical manifestations range from mild erythema
and discontinuous smoothening with small scales (h) to severe erythema with confluent
smoothening and large scales (i).

Distinguishing features identified in all of these subjects and only rarely in other subjects
with autosomal recessive congenital ichthyosis include tapered digits, hyperconvex nails
and malformation of the auricle (Fig. 2d-g).
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Additional characteristic features include pruritus (87%), anhidrosis (87%), skin pain
(76%) and skin infections (62%) (Table 1a). The presence of collodion membrane at birth
(OR 0.31, p=0.006) and alopecia (OR 0.24, p=0.007) are negatively associated with
NIPAL4 mutations (Table 1a).

PNPLA1
PNPLA1 encodes patatin-like phospholipase domain containing 1, which forms the
epidermal lipid barrier. 24 We identified 27 kindreds with mutations in PNPLA1. 14 are
compound heterozygous, 13 are homozygous and 13 mutations are novel.
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extensor surfaces of joints, particularly knees and elbows. (a-f) Distinguishing features
include thick, often functionally limiting, palmoplantar keratoderma. Skin findings range
from columnar hyperkeratosis most prominent in the intertriginous areas with mild
erythema (g) to confluent, organized or geometric exaggeration of coarse skin markings
with pink erythema and marked skin fragility (h and i). There is significant palmoplantar
keratoderma in all cases, ranging from moderate and smooth (j), moderate and patchy
(panel k), to severe and smooth palmoplantar keratoderma (panel l).

Additional characteristic features include skin pain (91%), skin odor (79%), pruritus
(70%), skin infections (57%) and anhidrosis (55%). Distinguishing features identified in
all subjects with KRT1 mutations and only rarely in others include thick, often
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functionally limiting palmoplantar keratoderma. The range of palmoplantar keratoderma
typically includes moderate and confluent scale with yellow thickening, moderate and
focal piled scale with yellow thickening, and thick, confluent yellow piled scale (Fig. 11
j-l).

To further expand the phenotypic spectrum, 26% of the IWC subjects in our cohort have
KRT1 mutations. All result in a frameshift, with 8% having a splice site mutation. In
contrast to those with IWC and KRT10 mutations, every IWC subject with KRT1
mutations had moderate or severe palmoplantar keratoderma. In addition, typical IWC-I
features such as malformed ears, hypoplastic nipples, ectropion and hypertrichosis were
absent among subjects with IWC and KRT1 mutations.

Overall, subjects with KRT1 mutations are less likely to be born with a collodion
membrane (OR 0.25, p=0.02) and experience eye problems (OR 0.22, p=0.02) or
alopecia (OR 0.13, p=0.02) compared to those without KRT1 mutations (Table 1b).

Palmoplantar ker atoder ma due to KRT1 and KRT10 mutations
It is widely accepted that palmoplantar keratoderma, when present in those with KRT10
mutations, is mild and smooth with occasional focal accentuation because KRT10 has
limited expression in the palmoplantar suprabasal epidermis. Prior studies have suggested
that KRT1 mutations lead to a limited cutaneous phenotype with predominant
palmoplantar presentation, while KRT10 mutations result in a more widespread cutaneous
involvement. 32 Our findings show that while palmoplantar keratoderma tends to be more
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chosen because they are usually less aggressively groomed and are thus more
representative.35 Given the phenotypic variability of scales in ichthyosis, we proceeded to
create two different types of scale standards: lamellar for flat scale and keratoderma for
columnar scale.35 A five-point Likert scale was used to represent severity.

Validation was conducted in two stages. First, 60 test photographs were sent to 10
dermatologists who independently scored all photographs for scale and erythema.35 Four
weeks later, the photographs were re-sent to the same raters to determine intra-rater
reliability. The second stage involved in-person validation at the annual June 2016
F.I.R.S.T. family conference in San Diego. 85 subjects were enrolled in the study.35
Participants were seen in one of three clinical exam rooms with four dermatologists in
each room. 12 dermatologists participated as raters and independently scored the
ichthyosis severity of each participant in their room.35 All raters for both stages were
experts in ichthyosis.

The inter-rater and intra-rater reliabilities were calculated with ICCs for absolute
agreement. In contrast to the Congenital Ichthyosis Severity Index study, we used more
stringent criteria to determine reliability. ICCs less than 0.7 were unacceptable, 0.7-0.9
was fair, 0.8-0.89 was good, and 0.9 or greater was excellent.

For both rounds of photographic scoring, scale scores were significantly correlated (ICCs
near 0.7 or greater) although the reliabilities for erythema were poor (ICCs <0.7). The
inter-rater reliability of choosing either lamellar or keratoderma scale type across all
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raters was determined by the Kuder-Richardson Formula 20 to be greater than 0.9 across
all four body sites. For the live validation stage, ICCs for both scale and erythema were
near or greater than 0.7. ICCs for combined and total scores for the four representative
sites were consistently above 0.7. These results validate the Visual Index for Ichthyosis
Severity as a reliable tool for scoring severity in all types of ichthyosis.

Remaining challenges and gaps
Although there are two validated ichthyoses severity assessment tools, each has its own
limitations. For instance, the Congenital Ichthyoses Severity Index only focuses on four
types of ichthyoses and does not represent the full spectrum of severity.34 The Visual
Index for Ichthyosis Severity has only been validated for four body sites and does not
adequately address the nuances of ichthyosis in darker-skinned patients.35 For example,
one of the limitations we discussed was that our photographic standards were chosen
from subjects with lighter, Fitzpatrick I-III skin types; ideally standards should include a
range of skin colors.35

There are additional unaddressed challenges. For instance, to date, no scale has been
validated to measure ichthyosis severity across the entire body. In addition, there is a
demand for a more comprehensive and user-friendly instrument that not only measures
ichthyosis severity in both adults and children but is also more representative of the
diverse community we serve.
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Given minimal regional variation in scale features among most body regions,
photographic scale standards were created for five body sites: elbows, knees, palms, soles
and torso (which can be applied to all other body regions) (Supplemental Figs. 3, 4, 5, 6,
7). Each standard included representations of all severity levels and all skin colors were
represented whenever possible. Professional photographers took the photographs of
ichthyosis patients at the Foundation for Ichthyosis and Related Skin Types (FIRST)
family conferences. The images were of uniform focus, magnification, positioning,
lighting and background, and represented subjects from all Fitzpatrick skin types.

We developed written descriptors characteristic of each severity level for erythema and
scale. Recognizing that scale features vary minimally among the various regions except
for palms and soles, we created two different sets of written scale descriptors: standards
for body regions excluding palms and soles and standards for palms and soles only
(Supplemental Fig. 8). Two ichthyosis experts (KC and AP) ensured that the descriptions
adequately captured the wide spectrum of scale features seen among the ichthyoses,
following FDA recommendations by employing morphological descriptors that
emphasized clear, non-overlapping and non-comparative categories.

The extent of ichthyosis, as measured by body region involvement, is also critical for
quantifying the baseline clinical disease burden and treatment efficacy. Since each body
region contributes uniquely to the total body surface area, the “rule of nines” was used to
assign each site a constant weighted value. These values varied for patients younger than
8 years and those 8 years and older. The final score is calculated by first multiplying the
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sum of scale (0-4) and erythema (0-4) by the multiplier for each body region, and then
adding the scores for all 10 regions. The final score ranges from 0 to 8 (Supplemental
Fig. 9).

ISS application
To aid in ease-of-use, we created iOS and Android ISS applications to assist researchers
and dermatologists in rapidly calculating site-specific and/or total-body severity scores
for both adults and children. It is available for download from the Apple application store
and the Google Play store.

Validation of the ISS
ISS validation was performed using scoring of test photographs, a different set of images
from the photographic standards. Six ichthyosis experts were each provided with detailed
scoring instructions, a score sheet and a hardcopy booklet of high-resolution photographs
of standards, test photos and accompanying descriptors. They then independently used
the ISS to score scale and erythema for 83 photographs (9 patients). The photographs
were then sent to the same dermatologists 4 weeks later to determine intra-rater
reliability. The 4-week period for the test-retest approach was chosen to reduce rater
recall of previous scoring.

Participants
This study was approved by the Yale Human Investigation Committee, consistent with
the Declaration of Helsinki guidelines. Written informed consent was obtained from all
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When analyzed according to body region, all inter-rater reliabilities for scale were in the
moderate-good category, with ICCs ranging from 0.503-0.898, except for elbows in
round 1 and lower extremities (excluding knees and soles) in round 2. Inter-rater
reliabilities for erythema were in the moderate-excellent category, with ICCs ranging
from 0.587-0.902. Complete descriptive statistics for ICC agreement and consistency
values during both rounds of testing are shown in Figures 14 and 15, respectively.

0.1
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Figure 14. ICCs for agreement for round 1 and 2 of photographic testing.
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Figure 15. ICCs for consistency for round 1 and 2 of photographic testing.
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Intra-rater reliability
Raters exhibited excellent intra-rater reliability, with an ICC of 0.954 (95% CI, 0.9180.974), 0.956 (95% CI, 0.925-0.974) and 0.913 (95% CI, 0.855-0.949) for the total, scale
and erythema scores, respectively.

When analyzed according to body region, all intra-rater reliabilities fell in the moderateexcellent category, with ICCs ranging from 0.642-0.952 for scale and 0.742-0.915 for
erythema.

Discussion
We have created a validated ISS for the comprehensive assessment of ichthyosis severity
in clinical trials and during patient treatment. Although several tools have been developed
and evaluated, none have been validated for use across the whole body. Our grading
system was designed with the goal of becoming the most reliable, comprehensive and
globally-adopted ichthyosis assessment tool. It needed to accurately measure severity
across ichthyoses of all genetic subtypes yet be simple to implement.

The ISS assesses scale and erythema over 10 body regions. In contrast, the VIIS is
limited to four body regions: upper arm, upper back, lower leg and dorsal foot.35 In
developing our grading system, it was evident these four sites alone do not sufficiently
capture a patient’s overall ichthyosis severity. Certain subtypes such as epidermolytic
ichthyosis exhibit only mild, generalized ichthyosis with scale mostly limited to the
palms and soles, sites that were not included in the VIIS. We also discovered that the
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palms and soles display unique scale morphology, including yellow thickening,
desquamative scale and fissuring. Therefore, these regions should be included when
assessing ichthyosis severity and deserve their own set of scale descriptors.

During both rounds of testing, soles exhibited the highest ICCs for scale. Palms had the
second and third highest ICCs for scale in round 1 and 2, respectively. The high interrater agreement is likely a reflection of the prominence of distinct scale features across
these sites and an indication that the descriptors adequately captures scale severity.
Elbows and lower extremities had the lowest ICCs for scale in round 1 and 2,
respectively. Scale on the elbows may have been challenging to assess because elbow
wrinkles may sometimes be difficult to distinguish from flat scale, especially in elderly
patients with increased skin laxity. The lower extremities saw poor-moderate inter-rater
agreement. One probable explanation for this finding is that the lower extremities
represent one of the largest surface areas and some raters may have scored the large
region based on the worst score for that site rather than an average, despite our
instructions indicating otherwise. Furthermore, some raters may have included the knees
in their assessment of lower extremities, despite written instructions indicating that the
lower extremities exclude the knees and soles. It is therefore not unreasonable to assume
that with prior completion of a training course, agreement among raters for these sites
would increase. Erythema ICCs for both rounds were all within the moderate-excellent
range.
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Overall, the ISS demonstrated excellent agreement among physicians. This is notable
given the heterogeneity of subjects analyzed. The inter-rater reliabilities for total score
and aggregate scale scores were near perfect (ICC>0.9). Inter-rater reliabilities for
aggregate erythema scores were also high (ICC>0.85). Importantly, individual evaluators
were consistent in their assessments of overall severity even after one month, a time span
not only long enough to reduce memory of prior scoring but also reflective of the timeframe for routine clinic follow-up. This consistency over time is essential for assessing
ichthyosis improvement and therapeutic efficacy.

Although there was excellent agreement among raters using the ISS, one limitation of our
study is that we validated the grading system using photographs, which may limit
physicians’ assessments of physical characteristics such as scale thickness and erythema.
The next step is to test the ISS in live settings. Another limitation is that only three of our
nine test patients had bald scalp photos. Scalp is a challenging site to assess given that
most patients have hair that can obscure scale and erythema. One way to circumvent this
challenge is to take advantage of the physical exam during in-person evaluations, which
if necessary, would also allow for the assessment of groin and buttocks—sites for which
we did not have test photos.

Even though two regions showed poor ICCs, the substantial inter-rater reliabilities for the
other eight body sites and the near-perfect agreement for total score demonstrate that the
ISS is a reliable tool for scoring ichthyosis severity across the entire body. It should also
be noted that the substantial inter-rater reliabilities were achieved without training the
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Elbows and knees
 Elbows: Includes attachment of the humerus to the proximal radius and ulna. It
excludes antecubital fossa.
 Knees: Includes attachment of the femur to the tibia and patella. It excludes the
popliteal fossa.

Palms: extends from the tip of the phalanges to the carpal bones (wrist joint) and
includes the area between the five phalanges. It includes glabrous skin.

Soles: extends from the tip of the toes to the calcaneus (heel). It includes glabrous skin.
By contrast, because erythema can be obscured by scale, the erythema score for a
particular region should be the worst score for that region.
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S e ve rity s c o re 1:
Mild: Ba re ly
pe rce ptible pink

S e ve rity s c o re 2:
Mode ra te : P ink to re d

S e ve rity s c o re 3:
S e ve re : Bright re d

S e ve rity s c o re 4:
Ve ry s e ve re : De e p re dpurple
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Supplemental Figure 3. Elbows photographic standards
Elbows: scale severity level 1

Normal skinintermixedwithsmall scalesor
areasof minimallyshiny/waxy/thickenedskinand/or
partial lossof normal skinmarkings

32

Supplemental Figure 4. Knees photographic standards

Sun 52
Supplemental Figure 5. Palms photographic standards
Pa lm s s c a le s e v e r it y le v e l 1

Minimal, confluent or focal thickening with continued
visibility of normal skin lines. May have minimal
desquamative scale.

40
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Supplemental Figure 6. Soles photographic standards.
So l e s s c a l e s e v e r i t y l e v e l 1

Minimal, confluent or focal thickening with continued
visibilityof normal skin lines. Mayhaveminimal
desquamativescale.

44

Sun 54

Sc a l e s e v e r i t y l e v e l 2

Several areasof scaling uponabackgroundof
mildlythickenedskin oftenwithsomelossof
normal skinmarkings

29
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Supplemental Figure 8. Written descriptions of each severity level for all sites except
palms and soles and for palms and soles only
Scale descriptors for all sites except the palms and soles
0

Normal skin; no perceptible scale, and no loss of normal skin markings

1

Normal skin intermixed with small scales or areas of minimally
shiny/waxy/thickened skin and/or partial loss of normal skin markings

2

Several areas of scaling upon a background of mildly thickened skin often
with some loss of normal skin markings

3

Confluent scales with or without focal areas of thick, piled scales and
moderately thickened skin

4

Extensive areas of confluent, primarily thick, piled scale and severely
thickened skin
25
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Supplemental Figure 9. Final score calculations for individuals younger than 8 years
(top) and those 8 years and older (bottom).
Body region
Head
Scalp
Face
Neck
Trunk
Chest/back/
abdomen
Groin
Upper extremities
Palms
Elbows
Arms(including
dorsal hands)
Lower extremities
Knees
Soles
Legs(including
dorsal feet/buttocks)
Final Score:

Scale
(0-4)

Multiplier

Erythema
(0-4)

Multiplier

X0.067
X0.067
X0.067

+
+
+

X0.067
X0.067
X0.067

X0.297

+

X0.297

X0.003

+

X0.003

X0.004
X0.004
X0.192

+
+
+

X0.004
X0.004
X0.192

X0.012
X0.009
X0.279

+
+
+

X0.012
X0.009
X0.279

Scoreper region

________
(0-8)
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